Denosumab Dosing Delays Tied to Increased Fracture Risk

Kristine Ensrud, MD, and John Schousboe, MD, PhD, from University of Minnesota note that during the COVID-19 pandemic, some organizations recommend transitioning to an oral bisphosphonate in patients on denosumab who can’t continue on time.

“Patients discontinuing denosumab treatment should transition to an alternative antiresorptive medication. The optimal timing and dosing of antiresorptive therapy after denosumab withdrawal is currently being investigated in randomized trials,” they write.

References

Lyu H, Yoshida K, Zhao SS, et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: A population-based cohort study. Ann Intern Med. 2020 Jul 28. Online ahead of print.
Lyu H, Yoshida K, Zhao SS, et al. Delayed denosumab injections and bone mineral density response: An electronic health record-based study. J Clin Endocrinol Metab. 2020 May 1;105(5):1435–1444.
Ensrud KE, Schousboe JT. Delayed denosumab injections and fracture risk. Ann Intern Med. 2020 Jul 28. Online ahead of print.

Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

Patients with osteoporosis and impaired renal function are at risk

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…

Unexpected Benefits of Bisphosphonates after Hip Fracture

Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Denosumab Does Not Increase Risk of Infection in RA Patients

Related Articles